PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.

[1]  A. Rosenwald,et al.  Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL) , 2019, Blood.

[2]  R. Greil,et al.  Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial , 2019, Blood.

[3]  A. Rosenwald,et al.  Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. LaCasce,et al.  Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma. , 2019, Blood.

[5]  R. Bouabdallah,et al.  PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. , 2019, The Lancet. Oncology.

[6]  K. Savage,et al.  Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study , 2018, Blood.

[7]  M. Federico,et al.  Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018 .

[8]  Chad A. LaGrange,et al.  NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  R. Greil,et al.  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.

[10]  J. Raemaekers,et al.  Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Michael Hauptmann,et al.  Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. d'Amore,et al.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.

[14]  J. Raemaekers,et al.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. , 2015, The New England journal of medicine.

[15]  J. Raemaekers,et al.  Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. , 2015, The Lancet. Haematology.

[16]  J. Raemaekers,et al.  Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. , 2015, JAMA internal medicine.

[17]  J. Radford,et al.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[18]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[19]  H. Eich,et al.  Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.

[20]  V. Diehl,et al.  Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  V. Diehl,et al.  Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  H. Amthauer,et al.  Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.

[23]  R. Greil,et al.  Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Greil,et al.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[26]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[27]  M. D. De Bruin,et al.  Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. , 2008, Journal of the National Cancer Institute.

[28]  J. Raemaekers,et al.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2007, The New England journal of medicine.

[29]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Horwich,et al.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.

[31]  E. Noordijk,et al.  Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Dirk Hasenclever,et al.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.